Corticotropin-releasing hormone (CRH) is decreased in the basal ganglia in Huntington's disease.
Corticotropin-releasing hormone-like immunoreactivity (CRH-IR) was measured in control and Huntington's disease brain tissues obtained postmortem. The concentration of CRH-IR was markedly decreased in the caudate/putamen in Huntington's disease; the concentration of somatostatin-like immunoreactivity measured in the same extracts was significantly increased in the caudate/putamen in Huntington's disease compared with the control group. In contrast to previously reported decreases in CRH-IR in the cerebral cortex in Alzheimer's disease, Parkinson's disease and progressive supranuclear palsy, no significant differences were observed in the concentrations of CRH-IR between controls and Huntington's disease in frontal, parietal, temporal, occipital and cingulate cortex and in globus pallidus.
D000328:Adult; D000368:Aged; D001479:Basal Ganglia / Q000378:metabolism* / Q000473:pathology; D003346:Corticotropin-Releasing Hormone / Q000378:metabolism*; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000378:metabolism* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011863:Radioimmunoassay; D012016:Reference Values; D013004:Somatostatin / Q000032:analysis
D013004:Somatostatin; D003346:Corticotropin-Releasing Hormone